Core Viewpoint - Soleno Therapeutics, Inc. has faced a significant decline in share price following a critical report by Scorpion Capital, which raised serious concerns about the safety and commercial viability of its drug VYKAT™ XR [1][4]. Company Overview - Soleno Therapeutics is focused on developing treatments for Prader-Willi syndrome, with its primary product being VYKAT™ XR, a once-daily oral tablet aimed at treating hyperphagia, a condition associated with the syndrome [2][4]. Investigation Details - Hagens Berman has initiated an investigation into Soleno to determine if the company misled investors regarding the safety and commercial prospects of VYKAT™ XR [2][3][6]. - The investigation will scrutinize Soleno's statements about the drug's safety and its commercial potential, particularly in light of recent adverse reports [3][6]. Critical Report Findings - Scorpion Capital's report highlighted a concerning trend of children being hospitalized for potential heart failure after using VYKAT™ XR, suggesting that the drug may face market withdrawal or a significant drop in new prescriptions [4][5]. - The report characterized Soleno as a "one-trick pony," emphasizing the lack of other meaningful assets or scientific programs, and warned of the company's potential demise if VYKAT™ XR fails, especially with its core patent expiring in 2026 [4][5]. Concerns Raised - Scorpion Capital criticized Soleno's launch metrics as misleading and pointed to a controversial physician involved in key trials, suggesting potential issues with data integrity and scientific standards [5][6]. - Allegations were made regarding irregularities in the physician's co-authored papers, which could undermine the validity of Soleno's trials and FDA submissions [5].

Core Viewpoint - A securities class action lawsuit has been filed against Lockheed Martin Corporation, alleging misleading statements regarding the company's financial performance and internal controls, particularly in its Aeronautics and Rotary and Mission Systems segments, leading to significant investor losses [1][2][6]. Group 1: Lawsuit Details - The lawsuit, Khan v. Lockheed Martin Corporation, seeks to represent investors who acquired Lockheed Martin securities between January 23, 2024, and July 21, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for September 26, 2025 [2]. - The lawsuit focuses on the accuracy of Lockheed Martin's statements regarding its Aeronautics and RMS business segments [2]. Group 2: Financial Performance Issues - Lockheed Martin reported $1.8 billion in pre-tax losses in its Aeronautics segment for the year ended December 31, 2024, citing "performance issues" [4]. - On July 22, 2025, the company announced an additional $950 million in pre-tax losses in the Aeronautics segment and $570 million in the RMS segment due to issues with the Canadian Maritime Helicopter Program [5]. - Following these announcements, Lockheed Martin's share price fell nearly 11% on July 22, 2025 [1]. Group 3: Allegations of Misleading Statements - The complaint alleges that Lockheed Martin made false and misleading statements while failing to disclose critical information about its financial health and operational risks [3][7]. - Specific allegations include a lack of effective internal controls regarding risk-adjusted contracts and an overstatement of the company's ability to meet contractual commitments [7]. - The investigation is focused on whether the company misled investors about the extent of its performance and financial problems [6].

Core Viewpoint - Telix Pharmaceuticals Limited is under investigation by the SEC, leading to a significant drop in the price of its American Depositary Shares after the announcement on July 23, 2025 [1][4]. Group 1: SEC Investigation - The SEC is investigating Telix regarding its disclosures related to the development of its prostate cancer therapeutic candidates [4]. - The investigation was triggered by Telix's announcement on July 22, 2025, which revealed the SEC's scrutiny [4]. Group 2: Shareholder Response - Hagens Berman, a national shareholders rights firm, has initiated an investigation to determine if Telix misled investors about its drug candidates [2][5]. - The firm is encouraging investors who have suffered substantial losses to come forward and submit their losses [2][5]. Group 3: Whistleblower Information - Individuals with non-public information about Telix are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery [7].

Core Viewpoint - Sable Offshore Corp. is facing a securities class-action lawsuit for allegedly misleading investors to inflate its stock price prior to a significant secondary offering, linked to the company's efforts to restart operations at its San Ynez Unit assets, which have been inactive since 2015 [1][4]. Group 1: Lawsuit Details - The lawsuit claims that on May 19, 2025, Sable announced it had "restarted oil production at SYU," leading to a 12.5% increase in its stock price in one day. This announcement was followed by a secondary stock offering that raised $256.5 million [2]. - A letter from California's Lieutenant Governor accused Sable of misrepresenting the nature of its activities, stating that the "restart" was merely well-testing procedures required before actual operations could resume. This letter was reported on May 28, causing Sable's stock to drop over 15% the following day, erasing the previous gains [3]. Group 2: Investigation and Accountability - The litigation aims to hold Sable accountable for allegedly raising capital under false pretenses, with the case being litigated in the U.S. District Court for the Central District of California [4]. - Hagens Berman, the law firm leading the investigation, is looking into whether Sable misled investors regarding its progress in restarting operations at SYU [4].

Core Viewpoint - Telix Pharmaceuticals Limited has faced a significant drop in the price of its American Depositary Shares following the announcement of an SEC subpoena related to its disclosures about prostate cancer therapeutic candidates [1][3]. Group 1: SEC Investigation - The SEC is investigating Telix regarding its statements about the development of its prostate cancer therapeutic candidates, which has raised concerns among investors [3]. - The investigation was triggered by Telix's announcement on July 22, 2025, which led to a sharp decline in share price during intraday trading on July 23, 2025 [3]. Group 2: Shareholder Response - Hagens Berman, a national shareholders rights firm, has initiated an investigation to determine if Telix misled investors about its drug candidates and is urging affected investors to report their losses [2][4]. - The firm is also seeking individuals with knowledge that could assist in the investigation, emphasizing the importance of whistleblower information [4]. Group 3: Legal and Financial Context - Hagens Berman has a history of securing substantial recoveries for investors, having achieved over $2.9 billion in similar cases [5]. - The firm is encouraging whistleblowers to consider their options under the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery [4].

Core Viewpoint - Napco Security Technologies, Inc. is facing significant challenges, including a 21% decline in share price year-to-date, amid legal scrutiny and operational difficulties, particularly related to a securities class action lawsuit concerning its distribution practices and sales forecasting [1][2]. Financial Performance - Napco's third-quarter results for fiscal year 2025 showed a 10.8% year-over-year decrease in net sales, totaling $43.96 million, while earnings per share exceeded expectations at $0.36 compared to a forecast of $0.29. However, net income fell by over 23% year-over-year, attributed to inventory reductions by key distributors [2][4]. - The company reported a 25% drop in equipment sales in its February 3, 2025 earnings report, leading to a withdrawal of its 45% EBITDA margin target for fiscal 2026, which resulted in a 26% decline in share price in a single trading session [4][6]. Legal Issues - A class action lawsuit, Patel v. Napco Security Technologies, Inc., alleges that the company's leadership misled investors regarding its ability to forecast hardware demand and maintain margin targets, failing to disclose vulnerabilities in its distribution network [3][5]. - The lawsuit claims that optimistic statements about sales and margins were misleading, leading to inflated stock prices during the class period and substantial losses when the true financial situation was revealed [5][8]. Investigation - Hagens Berman, a shareholder rights firm, is investigating the allegations against Napco, focusing on whether the company misled investors about its sales forecasting and distribution practices [8][9].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet demand for its cancer treatments [1][2]. Group 1: Lawsuit Details - The lawsuit, Farberov v. Iovance Biotherapeutics, Inc., claims that the company made overwhelmingly positive statements while concealing material adverse facts regarding its operational readiness [2][5]. - The class period for the lawsuit is from May 9, 2024, to May 8, 2025, with a lead plaintiff deadline set for July 14, 2025 [2]. Group 2: Stock Performance - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, falling from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. Group 3: Financial Performance - In its July 2024 announcement, Iovance attributed the lower revenue guidance to a month-long reduction in manufacturing capacity due to maintenance, lower-than-expected sales of Proleukin, and a variable pace in the treatment of patients with newer therapies [4]. Group 4: Investor Claims - Investors argue that the disclosures revealed previously concealed issues that negatively impacted the company's growth prospects, contradicting earlier positive statements about its operational readiness [5].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet market demand for its cancer treatments [1][2]. Company Overview - Iovance Biotherapeutics is a biotechnology firm that specializes in cancer treatments [1]. - The lawsuit claims that the company and its executives made overly positive statements while concealing material adverse facts about its operational readiness [2][5]. Legal Proceedings - The class action lawsuit is titled Farberov v. Iovance Biotherapeutics, Inc., et al., and covers the period from May 9, 2024, to May 8, 2025 [1][2]. - The lead plaintiff deadline for the lawsuit is set for July 14, 2025 [2]. Financial Impact - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. - The company attributed its lower revenue guidance to a significant reduction in manufacturing capacity and lower-than-expected sales of its existing therapy, Proleukin [4]. Allegations of Misleading Information - The lawsuit argues that the disclosures made by Iovance revealed previously concealed issues that negatively impacted the company's growth prospects [5]. - Investors contend that earlier positive statements misrepresented Iovance's operational readiness and commercialization efforts [5].

Core Viewpoint - A class-action lawsuit has been filed against Zynex, Inc. alleging that the company misled investors by inflating revenue through excessive and unnecessary shipments of medical supplies to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Tuncel v. Zynex, Inc., seeks to represent individuals and entities who purchased Zynex securities between March 13, 2023, and March 11, 2025, with a lead plaintiff deadline of May 19, 2025 [2][3]. - The complaint alleges that Zynex engaged in a scheme to inflate reported revenue by sending more products than medically necessary, which drew scrutiny from insurers like Tricare [3][4]. - Following a report in the medical journal STAT detailing Zynex's alleged oversupplying scheme, the company's stock price fell by over 5% [4]. Group 2: Financial Impact - Zynex disclosed a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [5]. - The announcement of the revenue shortfall led to a sharp decline in Zynex's share price, which plummeted by more than 51% [5]. - In Q1 2025, Zynex reported net revenue of $26.6 million, down from $46.5 million in the same period of 2024, with a gross profit margin contracting to 69% from 80% [6]. Group 3: Future Outlook - Zynex has issued a muted revenue guidance of $27 million for Q2 2025 and anticipates an earnings per share (EPS) loss of $0.20, withholding full-year financial guidance due to uncertainty with Tricare [8]. - The CEO of Zynex acknowledged the impact of the Tricare payment suspension on revenue and indicated that the company is initiating a restructuring effort [7].

SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Semtech Corporation (NASDAQ: SMTC) is navigating a turbulent period, facing a securities class-action lawsuit alleging investor deception regarding its CopperEdge product line. Recent comments from the company’s CEO during the Q4 2025 earnings call have brought the company's close relationships with key customers into sharper focus, raising questions about prior awareness of product-related challenges. Hagens Berman is investigating the alleged claims and ur ...